Here's the latest news from Santéand its portfolio companies
Portfolio
Geneos Therapeutics Announces Scientific Meeting Presentation of Sustained Immunosurveillance and Progression-free Survival in Two Brain Cancer Patients Treated with Neoantigen Targeted Personalized DNA Immunotherapy
Portfolio
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer
Portfolio
Exclusive: Astellas partners with Boston ‘miniproteins’ startup
Portfolio
Solu Therapeutics Initiates Dosing in Acute Myeloid Leukemia Cohort of the Ongoing Phase 1 Study of STX-0712
Portfolio
VS3 System Receives FDA Breakthrough Device Designation to Treat Debilitating Pulsatile Tinnitus
Portfolio
Sensorium Therapeutics Announces Positive Phase 1a Data for SNTX-2643 Showing Rapid and Sustained CNS Pharmacodynamic Activity
Portfolio
Kestrel Therapeutics Receives FDA Fast Track Designation for KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in the treatment of KRAS-Mutant Advanced Solid Tumors
Santé
ReEmerge, Inc. Exits Stealth with Oversubscribed $37M Series A to Challenge the Limitations of Chronic Cognitive Impairment Caused by Brain Injuries
Santé
Jaguar LAA, Inc. Announces Acquisition of Assets Related to the Laminar Program
Santé
Biotech Investing At The Earliest Stages With Santé Ventures’ Omar Khalil
Santé
Biotech Venture Funding Roars Back
Portfolio
RapidPulse Secures Oversubscribed $48M Series B Financing to Advance Clinical Development of Next-Generation Stroke Aspiration Technology
Portfolio
Surgical Safety Technologies Becomes Aimbient, Expanding Ambient AI Across the Procedural Environment
Portfolio
Endogenex Announces Full Enrollment of the ReCET Clinical Study
Portfolio
Reimagine Care and The Center for Cancer and Blood Disorders Redefine Support for Patients on Advanced Cancer Therapies
Portfolio
Endovascular Engineering Collects $80 Million in Funding
